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Sirolimus-eluting stents versus standard stents in patients with stenosis
in a native coronary artery
Moses JW, Leon NB, Pomma JJ, et al. N Engl J Med 2003;349:1315-23.
Conclusion: Sirolimus-eluting stents in patients with complex coro-
nary artery disease reduced the rate of recurrent stenosis and related clinical
events in all subjects analyzed, including patients with diabetes, patients with
longer coronary lesions, and patients with small coronary arteries.
Summary: Sirolimus (Rapamycin) is a cytostatic lactone with antipro-
liferative and anti-inflammatory properties. When delivered via a polymer-
encapsulated stent it reduces risk for restenosis in patients undergoing
coronary artery stenting who are at low risk for restenosis. In this study the
authors investigated the utility of Sirolimus-eluding stents in patients with
more complex coronary lesions at greater risk for restenosis.
This was a randomized double-blind clinical trial comparing Sirolimus-
eluting stents with standard stents in 1058 patients. Fifty-three centers in the
United States were used. All patients had a newly diagnosed lesion in a native
coronary artery. Twenty-six percent of the patients included in this study had
diabetes, many had longer coronary artery lesions (mean, 14.4 mm), and
many had small vessels (mean, 2.8 mm). The primary end point was failure
of the target vessel within 270 days after stent implantation. Failure was
defined as death from cardiac causes, Q-wave or non-Q-wave myocardial
infarction, or revascularization of the target vessel with either open coronary
surgery or repeat coronary angioplasty.
Target vessel failure was reduced from 21% with the standard stent to
8.6% with Sirolimus-eluting stents (P  .001). This end point was driven
largely by the decreased frequency of target vessel revascularization in
patients with the drug-eluting stents (16.6% in the standard stent group vs
4.1% in the Sirolimus stent group; P  .001). Results in favor of the
Sirolimus-eluting stent held for all subgroups, including the patients with
diabetes, those with smaller vessels, and those with more complex coronary
lesions. Three-hundred fifty patients in the Sirolimus stent group and 353 in
the standard stent group had angiographic follow up. The frequency of
in-stent restenosis of at least 50% lumen diameter was 35.4% in the standard
stent group and 3.2% in the Sirolimus stent group (P  .001).
Comment: The study indicates a consistent and powerful treatment
effect of Sirolimus-eluting stents in patients with complex coronary lesions
out to 270 days. Longer follow-up is clearly required. Short-term benefits do
not always translate into long-term benefits.
Evaluation of D-dimer and the diagnosis of suspected deep vein throm-
bosis
Wells PS, Anderson DR, Rodger M, et al. N Engl J Med 2003;349:1227-35.
Conclusion: The combination of a D-dimer assay and a clinical predic-
tion model of the possibility of deep venous thrombosis (DVT) can safely
reduce the number of ultrasound examinations required in the evaluation of
patients with possible DVT.
Summary: D-dimer fragments are produced during degradation of
fibrin clots, and suggest the presence of thrombosis. Different assays vary in
their sensitivity for detection of D-dimer and in their ease of use and expense.
It is postulated that D-dimer assays with high negative predictive values for
DVT may be useful in the evaluation of patients with possible DVT, perhaps
permitting avoidance of ultrasound testing in some patients with a negative
assay. It has also been shown that a clinical probability scoring system can be
used, along with a single negative ultrasound examination, to rule out DVT
in patients whose probability score suggests a low likelihood of DVT.
Outpatients with suspected lower extremity DVT were categorized as
likely or unlikely to have DVT. Patients were then randomly assigned to
undergo ultrasonography alone (control group, n 530) or D-dimer testing
(D-dimer group, n 569) followed by ultrasonography, unless the D-dimer
test was negative and the patients’ clinical probability scores suggested they
were unlikely to have DVT. In these cases duplex scanning for DVT was not
performed. D-dimer testing was performed with the SimpliRED assay (Agen
Biomedical) or IL test (Instrumentation Laboratory).
The prevalence of DVT was 15.7%. In patients in whom DVT was ruled
out with the initial diagnostic strategy, over the next 3 months there were two
confirmed venous embolic events in the D-dimer group (0.4%) and six in the
control group (1.4%; P .16). D-dimer testing lowered the use of ultrasonog-
raphy from a mean of 1.34 tests per patient in the control group to a mean of
0.78 tests per patient in the D-dimer group (P .008). Thirty-nine percent of
patients in the D-dimer group did not require ultrasound imaging.
Comment: This study indicates that it is possible to safely omit venous
ultrasound studies in highly selected patients with a low probability of DVT.
Implementation of this protocol may allow vascular laboratories to reduce
after-hours venous duplex studies and to improve working conditions and
retention of vascular technologists.
Vascular access outcomes using the transposed basilic vein arterio-
venous fistula
Segal JH, Kayler LK, Henke P, et al. Am J Kidney Dis 2003;42:151-157.
Conclusion: Patency rates for transposed basilic vein arteriovenous fistulas
(TBAVF) are not so good as those initially reported in smaller studies.
Summary: The authors performed an analysis of TBAVFs to determine
patency rates and risk factors for primary failure. This was a retrospective analysis
of 99 patients who had TBAVFs created for hemodialysis access between April
1997 and October 2001. In 46% of the patients this was the initial access.
Patient mean age was 55 years, and 46% were male. Primary patency rates for
TBAVFs at 1 and 2 years were 47% and 41%, and assisted patency rates were 64%
and 58%, respectively. In 23% of cases there was primary failure of the TBAVF.
Unassisted access patency was worse in patients who had a previous access
(relative risk [RR], 2.04; 95% confidence interval [CI], 1.09-3.85; P .03) and
in patients who had an ipsilateral central venous catheter (RR, 2.92; 95% CI,
1.34-6.38; P  .01). Primary access failure was increased by the presence of
older age (RR, 2.0), obesity (RR, 7.1), and previous dialysis access (RR, 6.4).
Steal syndrome necessitating intervention occurred in 5% of cases.
Comment: This study represents the largest single-center evaluation of
TBAVFs for dialysis access. The reported results are similar to those reported in
a comparison of prosthetic grafts, autogenous fistulas, and venous transpositions
from the United States Renal Data System Dialysis Morbidity and Mortality
Study published in The Journal in 2001. The current results, however, are
inferior to some studies reporting unassisted patency rates as high as 90% in 1
year (Hakaim AG, et al, J Vasc Surg 1998;27:154-7). Given the results of
national data, it is likely the authors’ assisted and unassisted patency rates are
reflective of what will be achieved in most centers with the use of TBAVFs for
dialysis access. This paper is important in that it highlights certain patient groups
that may not receive substantial benefit over prosthetic grafts with the use of
TBAVFs. It suggests the need for a multicenter prospective randomized trial
evaluating the efficacy of TBAVFs versus prosthetic grafts in patients who are
older, obese, or have had previous vascular access.
Collagen- versus gelatin-coated Dacron versus stretch PTFE bifurca-
tion grafts for aortoiliac occlusive disease: Long-term results of a
prospective, randomized multicenter trial
Preager MR, Hoblaj T, Nanobashbili J, et al. Surgery 2003;134: 80-5.
Conclusion: There are no patency differences when knitted, gelatin-
coated Dacron, knitted collagen-coated Dacron, and stretch polytetrafluo-
roethylene (PTFE) aortic grafts are compared for the treatment of aortoiliac
occlusive disease.
Summary: This was a randomized multicenter trial at three tertiary
referral centers, comparing the patency of knitted, gelatin-coated Dacron,
knitted collagen-coated Dacron, and stretch PTFE aortic bifurcation grafts.
Fifty-two patients received the gelatin-coated Dacron graft, 49 patients the
collagen-coated Dacron graft, and 48 patients the PTFE graft. Thirty-day
operative mortality was 4%. No intraoperative deaths occurred. Mean fol-
low-up was 97 months.
At 8 years, primary patency for the knitted gelatin-coated Dacron grafts
was 77%, primary patency for the collegen-coated Dacron grafts was 78%,
and primary patency for the PTFE grafts was 79% (P .8). There was also no
significant difference in secondary 8-year patency rates (91%, gelatin-coated
Dacron grafts; 96%, collagen-coated Dacron grafts; and 90%, PTFE grafts;
P  .5). None of the patients in this study were thought to have hypoplastic
aortic syndrome, and none needed grafts smaller than 14/7 mm. Overall
there were six graft infections, five in Dacron grafts and one in a PTFE graft.
Four percent of grafts became infected during follow-up.
Comment: Statistically there was no difference between the Dacron
and PTFE grafts (P  .05) in terms of infection. The trend, however, is
worrisome, and further studies evaluating relative infection rates of Dacron
and PTFE grafts in the aortic position seem warranted. The authors’
conclusion that the three graft materials do not differ in terms of long-term
patency, complications, or risks for infection seems warranted. However, a
type II error may be masking a difference in relative infection rates between
Dacron and PTFE grafts.
Cerebral hemodynamics in asymptomatic and symptomatic patients
with high-grade carotid stenosis undergoing carotid endarterectomy
Soinne L, Helenius J, Tatlisumak T, et al. Stroke 2003;34:1655-61
Conclusion: Hemodynamic adaption to high-grade carotid stenosis is
inferior in patients with symptomatic carotid stenosis compared with those
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